©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Cardiol. Jul 26, 2025; 17(7): 107539
Published online Jul 26, 2025. doi: 10.4330/wjc.v17.i7.107539
Published online Jul 26, 2025. doi: 10.4330/wjc.v17.i7.107539
Breaking barriers: Neprilysin inhibition in chronic cardiorenal syndrome
Olesya Ilkun, Amir Kazory, Division of Nephrology, Hypertension, and Renal Transplantation, University of Florida, Gainesville, FL 32610, United States
Author contributions: Both Ilkun O and Kazory A searched the literature, designed, wrote, edited, and revised the manuscript; Kazory A submitted the manuscript.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
Corresponding author: Amir Kazory, Professor, Division of Nephrology, Hypertension, and Renal Transplantation, University of Florida, 1600 Sw Archer Rd Box 100224, Gainesville, FL 32610, United States. amir.kazory@medicine.ufl.edu
Received: March 26, 2025
Revised: April 29, 2025
Accepted: June 16, 2025
Published online: July 26, 2025
Processing time: 119 Days and 0.3 Hours
Revised: April 29, 2025
Accepted: June 16, 2025
Published online: July 26, 2025
Processing time: 119 Days and 0.3 Hours
Core Tip
Core Tip: Patients with advanced chronic kidney disease and end-stage kidney disease face disproportionally high rates of heart failure and mortality. Currently, there is an unmet need for medical therapies for heart failure in these populations. This review summarizes information regarding the safety and efficacy of the use of angiotensin receptor/neprilysin inhibition in patients with heart failure with reduced ejection fraction and advanced chronic kidney disease or end-stage kidney disease to help guide safe clinical management.